Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis - Test2 - elhamkhani - TriplyDB

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

http://www.wikidata.org/entity/Q28271008

about

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review New and emerging disease modifying therapies for multiple sclerosis N-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune Encephalomyelitis Multiple Sclerosis: Where Will We Be in 2020?Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach Fingolimod for relapsing-remitting multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Pharmacological treatment for memory disorder in multiple sclerosis Fingolimod for relapsing remitting multiple sclerosis Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine The role of sphingosine-1-phosphate transporter Spns2 in immune system function Atacicept: targeting B cells in multiple sclerosis The emerging role of FTY720 (Fingolimod) in cancer treatment Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis Optimizing treatment success in multiple sclerosis The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis Importance of Apolipoprotein A-I in Multiple Sclerosis Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Newer therapies for multiple sclerosis Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group Novel Insights and Therapeutics in Multiple Sclerosis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Sphingosine 1-phosphate receptor modulators in multiple sclerosis Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Multiple sclerosis-a quiet revolution The human plasma lipidome Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use Stage-specific immune dysregulation in multiple sclerosis Sphingosine 1-phosphate signalling Lysophospholipids and their receptors in the central nervous system Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis

P2860

Q22241795-5E912D0A-C0C2-42F9-8A0A-7747C5BC4C16 Q22242305-BCE8545B-FC9E-4E97-BA5C-D06E051BA148 Q22248070-C79EDFA2-64A4-4E58-A4CF-763CDDF687A3 Q22252863-040E509B-A4D3-4C29-8DC7-B34B7B00A2BF Q22305854-356928C2-0B96-4E72-8769-A6ECC53EDFD5 Q24185882-19ADA52D-6FCD-4840-8EAA-C7F4937EF67A Q24187126-75EA53C5-45A1-475F-AB3E-97EC64C8A5DB Q24201735-81BCD4F0-AC6A-46C5-BE16-05F76541BF7F Q24236597-0A5EB3E3-8C78-4988-8BD6-868E57CAF156 Q24564715-9A514425-5A3C-4012-9308-D7C0EFEB53BB Q24597369-9B6FD7EF-4AD6-4DDD-8E3B-FCF0CA157A93 Q24599540-F25AD102-478A-457C-9BC6-14F005E5B0C0 Q24628925-1F1E00E2-65A8-4A59-AAA9-219D2EBDCBE0 Q26748927-E7A5F6A8-F393-42C3-B55D-A63022BB629E Q26752430-29003171-6BFE-4CD6-AF5A-51AF5DA01E41 Q26752466-7D62A1BB-8E54-45BA-9E5D-5D16D816CBA8 Q26752859-DB2B2C6E-5891-45C5-BE44-9599CCFE9C80 Q26765300-47B216AD-D31D-48F1-8FBF-F4B0B8505F8B Q26770664-2C78F513-D891-4FBD-BD29-78A22D03B63C Q26771635-E36ABA26-DA11-4F4D-8E04-39F2F0F5846C Q26771968-6815981E-F491-4E07-A62A-34796F1AFB30 Q26773978-CD2C1393-4A7A-4ECB-AFF6-B4C9E7920151 Q26774792-E4076E2F-8546-4CB3-8EDB-94D07966D366 Q26777329-A7D30AAB-7A46-48C5-9489-67D531615E40 Q26777686-63CA1715-A432-464C-A3F5-D1C81800D31C Q26779900-CB9B6AA3-E4A0-4001-ABBE-E4496DBDD374 Q26780412-F7B9B40C-EE01-45FF-BC1C-7E30DFFA7600 Q26784619-1758E0FE-FAB7-4B5D-ABB2-A0C2522B276A Q26798434-921991EE-4F39-421D-9BE0-8DB04D681DD6 Q26799440-52CDD7F1-2059-45E8-AC32-4DFB03982EE4 Q26800128-CBC8D1C2-2C0B-455E-9033-954380876A6C Q26822611-358B49C1-0F05-4553-90E7-C428FA8602C4 Q26826930-B5024CAB-6A07-432B-94AE-470A2EEEDC37 Q26830940-11473E5F-080D-48C1-A679-0DFA2320F405 Q26849781-1909CB84-B603-4BCB-999D-40987F2DF95B Q26852859-934C4F6A-520F-42B4-ABC3-F91540418DA6 Q26852942-D61136FE-5292-440B-85D7-382363CEE180 Q26859168-0664FE64-0CAD-417C-95DD-DC83CC87A98D Q26999417-8690F052-D6B5-4D9E-94A8-63A8E7380CAC Q27000269-F0A47828-7A58-46E8-B4F9-99893E2C2431

P2860

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

http://www.wikidata.org/entity/Q28271008

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@ast

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@en

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@nl

type

label

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@ast

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@en

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@nl

prefLabel

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@ast

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@en

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@nl

P1433

Q28271008-316AD184-F497-4180-9B09-BBAA689E5D47

P1476

Q28271008-D6D9C815-424F-4061-B9EF-55B4E086650E

P2093

Q28271008-23BC6AC7-2AED-4DC8-987F-8C8A419D585E

Q28271008-2D5B0ECA-2B70-47B3-ABAB-367968BC2601

Q28271008-57CDD864-3B95-4CA2-99BA-DB5B414E1133

Q28271008-7766D32A-D92B-4A05-965E-91B052E2F4AC

Q28271008-ACB59785-FC0C-4498-B390-5C236DD9FBE4

Q28271008-BC27BC86-F2B4-4B21-8D71-AF152165AA2C

Q28271008-C0011F5D-2453-4A07-A509-849062640E42

Q28271008-C080555C-8568-45A7-A0AB-C3038E2223A2

Q28271008-D29B0EBF-8668-48E2-BA5B-6C36ABB2F856

Q28271008-DC8D833F-6193-4E8C-97C0-16A2A3F827DF

P304

Q28271008-DB57977C-E907-43FB-8309-8500EB610689

P31

Q28271008-85EBF293-24EC-4E78-87A1-29ADFEA3E4E4

P3181

Q28271008-BBECC915-7069-48AB-AFBD-5469A0524170

P356

Q28271008-3FB179F1-E0DB-4E60-9C3C-FDF97195C4C3

P407

Q28271008-0E562C41-6765-4096-8962-43A75523587D

P433

Q28271008-1A1231AA-B523-45FA-99FA-B2F4F8231BF6

P478

Q28271008-DD1CBB7D-ABB0-4CB2-9592-1DB1E1B45B82

P50

Q28271008-2925BD18-345B-4A44-A7E7-4CF841608855

Q28271008-3C492729-9178-4521-BE36-C1FE745FEE87

Q28271008-4883D093-EED9-4766-BB92-591B709D1D48

Q28271008-8B6AAEF1-220C-49B9-9C6D-47120BF1AB85

P577

Q28271008-CF31790C-258C-4602-AEDA-D4406B87F6FB

P698

Q28271008-5FF8D1AB-22FF-4AE4-83AE-F28FFB018B75

P921

Q28271008-B5664B2E-E4AC-4D68-B6E2-07D2F5258610

P3181

P356

P1433

The New England Journal of Medicine

P1476

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

@en

P2093

Ana de Vera

http://www.w3.org/2001/XMLSchema#string

Bhupendra O Khatri

http://www.w3.org/2001/XMLSchema#string

Guillermo Izquierdo

http://www.w3.org/2001/XMLSchema#string

James Jin

http://www.w3.org/2001/XMLSchema#string

Jean Pelletier

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Cohen

http://www.w3.org/2001/XMLSchema#string

Klaus Tiel-Wilck

http://www.w3.org/2001/XMLSchema#string

Paolo Gallo

http://www.w3.org/2001/XMLSchema#string

Ruggero Capra

http://www.w3.org/2001/XMLSchema#string

Shreeram Aradhye

http://www.w3.org/2001/XMLSchema#string

P304

402-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

486740

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0907839

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

Frederik Barkhof

P577

2010-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20089954

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis